Document Type

STEM

Date

2015

Submission Date

July 2017

Abstract

This work is part of an ongoing study that investigates the upregulation of LTBP-1 in mammary epithelial cells as well as the differentiation of breast adipose stem cells (BASCs) in the presence of TGF-β1. Through immunofluorescence imaging, LTBP-1 is shown to co-localize with fibronectin fibrils in adipose stem cells. Previous work from our lab has shown that blocking fibronectin fibril formation can inhibit Epithelial-Mesenchymal Transition. Thus, targeting of fibronectin assembly could be a potent new therapeutic in cancer treatment. In the current work, we focus on the pharmacodynamics of a FN assembly inhibitor derived from the protein Adhesin F1 (refered to as FUD). FN Fibril area was quantified in samples with different FUD dosages to determine the optimal concentration. The optimal dosage for this inhibitor was obtained for both mammary epithelial cells and breast adipose stem cells through image processing. Additionally, toxicity studies were performed using MTT assays. Results suggest that in both the mammary epithelial cells and the breast adipose stem cells, there is a range of dosing for which FN fibril formation is blocked but toxicity is low.

Rights

© The Author(s)

Is Part Of

Auctus

Included in

Diseases Commons

Share

COinS